Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
Go back to Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)| (NASDAQ: ACRS) | Delayed: 6.06 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.06 | 52 Week High | $33.88 | |||
| Open | $6.06 | 52 Week Low | $14.12 | |||
| Day High | $6.06 | P/E | N/A | |||
| Day Low | $6.06 | EPS | $0.00 | |||
| Volume | 6 | |||||
